RAC - Charts & Price Action, page-13032

The SP is still far from reflecting the fundamentals, but it's been moving in the right direction lately.

I think the reasons are:
* buyback sandbags (without spending a cent so far, a brilliant concept)
* tax loss selling finished after 30 June
* Gold Coast presentation new investors
* oh yes, there was a string of excellent preclinical announcements, but that would be the smallest effect.

The only thing worrying me is that patients should have been lined up waiting for the EMD AML trial to start in Newcastle, but apparently that's not the case. The hospital has been ready since the induction on 31 May. There aren't any competing EMD AML treatments, and those patients are excluded from other AML trials. So if they've applied for another clinical trial and been rejected, they would know they have EMD. I suspect lack of interest by oncologists. (But I have absolutely no evidence that oncologists own shares in hospices.)